JP2010504344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504344A5 JP2010504344A5 JP2009529316A JP2009529316A JP2010504344A5 JP 2010504344 A5 JP2010504344 A5 JP 2010504344A5 JP 2009529316 A JP2009529316 A JP 2009529316A JP 2009529316 A JP2009529316 A JP 2009529316A JP 2010504344 A5 JP2010504344 A5 JP 2010504344A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- compound according
- propyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 3
- -1 2-methyl-2H- [1,2,4] triazol-3-yl Chemical group 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010001584 Alcohol abuse Diseases 0.000 claims 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- VOWVNYUDZKFEFL-UHFFFAOYSA-N N1=CC=CN2N=C(CCCC)C=C21 Chemical compound N1=CC=CN2N=C(CCCC)C=C21 VOWVNYUDZKFEFL-UHFFFAOYSA-N 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 201000003082 alcohol use disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- XVAWSBAQNIXMIO-UHFFFAOYSA-N tildacerfont Chemical compound CC1=NN2C(C(CC)CC)=CC(C)=NC2=C1C(=C(N=1)Cl)SC=1N1CCOCC1 XVAWSBAQNIXMIO-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (7)
- 3−[4−ブロモ−2−(2−メチル−2H−[1,2,4]トリアゾール−3−イル)−チアゾール−5−イル]−2,5−ジメチル−7−(1−プロピル−ブチル)−ピラゾロ[1,5−a]ピリミジンである、請求項1に記載の化合物またはその薬理学的に許容できる塩。
- 3−(4−ブロモ−2−(2−メチル−2H−[1,2,4]トリアゾール−3−イル)−チアゾール−5−イル)−7−(1−エチル−プロピル)−2,5−ジメチル−ピラゾロ[1,5−a]ピリミジンである、請求項1に記載の化合物またはその薬理学的に許容できる塩。
- 3−(4−クロロ−2−モルホリン−4−イル−チアゾール−5−イル)−7−(1−エチル−プロピル)−2,5−ジメチル−ピラゾロ[1,5−a]ピリミジンである、請求項1に記載の化合物またはその薬理学的に許容できる塩。
- 請求項1から請求項5のいずれか1項に記載の化合物またはその薬理学的に許容できる塩と、薬理学的に許容できる賦形剤とを含む、医薬組成物。
- 請求項1から請求項5のいずれか1項に記載の化合物またはその薬理学的に許容できる塩と、薬理学的に許容できる賦形剤とを含む、アルコール濫用または薬物濫用の治療のための医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82626406P | 2006-09-20 | 2006-09-20 | |
US60/826,264 | 2006-09-20 | ||
PCT/US2007/078605 WO2008036579A1 (en) | 2006-09-20 | 2007-09-17 | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010504344A JP2010504344A (ja) | 2010-02-12 |
JP2010504344A5 true JP2010504344A5 (ja) | 2010-10-28 |
JP5161226B2 JP5161226B2 (ja) | 2013-03-13 |
Family
ID=38924802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009529316A Active JP5161226B2 (ja) | 2006-09-20 | 2007-09-17 | Crf1受容体アンタゴニストとしてのチアゾールピラゾロピリミジン |
Country Status (34)
Country | Link |
---|---|
US (1) | US8030304B2 (ja) |
EP (1) | EP2094709B1 (ja) |
JP (1) | JP5161226B2 (ja) |
KR (1) | KR101088239B1 (ja) |
CN (1) | CN101516887B (ja) |
AR (1) | AR062886A1 (ja) |
AT (1) | ATE481405T1 (ja) |
AU (1) | AU2007297421B2 (ja) |
BR (1) | BRPI0717023B8 (ja) |
CA (1) | CA2663511C (ja) |
CL (1) | CL2007002693A1 (ja) |
CR (1) | CR10682A (ja) |
CY (1) | CY1110854T1 (ja) |
DE (1) | DE602007009305D1 (ja) |
DK (1) | DK2094709T3 (ja) |
EA (1) | EA015179B1 (ja) |
ES (1) | ES2350282T3 (ja) |
HK (1) | HK1132505A1 (ja) |
HR (1) | HRP20100516T1 (ja) |
IL (1) | IL197614A (ja) |
MA (1) | MA30798B1 (ja) |
MX (1) | MX2009003125A (ja) |
MY (1) | MY146388A (ja) |
NO (1) | NO20091489L (ja) |
NZ (1) | NZ575572A (ja) |
PE (1) | PE20081377A1 (ja) |
PL (1) | PL2094709T3 (ja) |
PT (1) | PT2094709E (ja) |
RS (1) | RS51545B (ja) |
SI (1) | SI2094709T1 (ja) |
TN (1) | TN2009000095A1 (ja) |
TW (1) | TWI402269B (ja) |
UA (1) | UA96458C2 (ja) |
WO (1) | WO2008036579A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP5524221B2 (ja) * | 2008-10-02 | 2014-06-18 | イーライ リリー アンド カンパニー | 合成中間体としてのチアゾリル−ピラゾロピリミジン化合物および関連合成方法 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3096756A1 (en) | 2014-01-21 | 2016-11-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
CN109906222B (zh) | 2016-09-07 | 2023-08-01 | 加利福尼亚大学董事会 | 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂 |
MX2019015318A (es) * | 2017-08-14 | 2020-07-20 | Spruce Biosciences Inc | Antagonistas del receptor del factor liberador de corticotropina. |
KR20200040761A (ko) | 2017-08-14 | 2020-04-20 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
JP7427655B2 (ja) * | 2018-04-27 | 2024-02-05 | スプルース バイオサイエンシーズ,インク. | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 |
CN109134481B (zh) * | 2018-08-07 | 2021-05-14 | 中山大学 | 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用 |
TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
TW202134241A (zh) * | 2019-12-04 | 2021-09-16 | 美商紐羅克里生物科學有限公司 | Crf受體拮抗劑及使用方法 |
GR1010096B (el) * | 2020-07-02 | 2021-10-08 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης |
CA3188730A1 (en) * | 2020-08-12 | 2022-02-17 | Christopher Barnes | Methods and compositions for treating polycystic ovary syndrome |
JP2023540223A (ja) | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crf受容体アンタゴニストおよび使用方法 |
US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
WO2023091684A1 (en) * | 2021-11-19 | 2023-05-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
WO2023163945A1 (en) * | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0674641T3 (da) | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidiner som CRF-antagonister |
WO1997029109A1 (en) * | 1996-02-07 | 1997-08-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as crf receptor antagonists |
RO121272B1 (ro) | 1996-07-24 | 2007-02-28 | The Du Pont Merck Pharmaceutical Company | Azolotriazine şi pirimidine |
PL195762B1 (pl) * | 1996-07-24 | 2007-10-31 | Bristol Myers Squibb Pharma Co | Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku |
CZ68199A3 (cs) | 1996-08-28 | 1999-11-17 | Pfizer Inc. | 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob |
EP1040831A3 (en) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
AU7737900A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
WO2002072202A1 (en) | 2001-03-13 | 2002-09-19 | Bristol-Myers Squibb Pharma Company | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
CA2550948A1 (en) | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
-
2007
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 EP EP07842582A patent/EP2094709B1/en active Active
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en active Application Filing
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active IP Right Cessation
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
-
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
-
2010
- 2010-01-08 HK HK10100143.4A patent/HK1132505A1/xx active IP Right Revival
- 2010-09-21 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown